Dose Escalation Study for Defining the Maximum Tolerated Dose of Continuous Oral Trofosfamide in Pretreated Patients with Metastatic Lung Cancer
Salah-Eddin Al-Batran(Goethe University Frankfurt), Eliézer Jäger(Krankenhaus Nordwest), D.H.J. Jager(Krankenhaus Nordwest), Antje Neumann(Krankenhaus Nordwest), Carolin Maria Frisch(Krankenhaus Nordwest), J. Orth, F. Bert(Krankenhaus Nordwest), A. Knuth(University Hospital Zurich), Akin Atmaca(Heidelberg University)
Cited by 5
Related Papers
Phase III Trial in Metastatic Gastroesophageal Adenocarcinoma with Fluorouracil, Leucovorin Plus Either Oxaliplatin or Cisplatin: A Study of the Arbeitsgemeinschaft Internistische Onkologie
|Journal of Clinical Oncology|2008|784
Induction of primary NY-ESO-1 immunity: CD8+ T lymphocyte and antibody responses in peptide-vaccinated patients with NY-ESO-1+ cancers
|Proceedings of the National Academy of Sciences|2000|427
Stromal Antigen Targeting by a Humanised Monoclonal Antibody: An Early Phase II Trial of Sibrotuzumab in Patients with Metastatic Colorectal Cancer
|Oncology Research and Treatment|2003|364